These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

187 related items for PubMed ID: 36332728

  • 1. A Banff-based histologic chronicity index is associated with graft loss in patients with a kidney transplant and antibody-mediated rejection.
    Haas M, Mirocha J, Huang E, Najjar R, Peng A, Sethi S, Vo A, Anglicheau D, Jordan SC, Rabant M.
    Kidney Int; 2023 Jan; 103(1):187-195. PubMed ID: 36332728
    [Abstract] [Full Text] [Related]

  • 2. Clinical and pathological analyses of transplant glomerulopathy cases.
    Shimizu T, Ishida H, Toki D, Nozaki T, Omoto K, Tanabe K, Honda K, Koike J.
    Nephrology (Carlton); 2014 Jun; 19 Suppl 3():21-6. PubMed ID: 24842817
    [Abstract] [Full Text] [Related]

  • 3. A Banff Component Scoring-based Histologic Assessment of Bortezomib-based Antibody-mediated Rejection Therapy.
    Sadaka B, Ejaz NS, Shields AR, Cardi MA, Wadih G, Witte D, Abu Jawdeh BG, Alloway RR, Woodle ES.
    Transplantation; 2015 Aug; 99(8):1691-9. PubMed ID: 25803498
    [Abstract] [Full Text] [Related]

  • 4. Acute Antibody-Mediated Rejection in Kidney Transplant Based on the 2013 Banff Criteria: Single-Center Experience in Uruguay.
    Nin M, Coitiño R, Kurdian M, Orihuela L, Astesiano R, Garau M, López D, Rievas G, Rodriguez I, González-Martínez F, Noboa O.
    Transplant Proc; 2016 Mar; 48(2):612-5. PubMed ID: 27110014
    [Abstract] [Full Text] [Related]

  • 5. Clinicopathological analysis of transplant glomerulopathy cases.
    Shimizu T, Ishida H, Shirakawa H, Omoto K, Tsunoyama K, Iida S, Tanabe K, Yamaguchi Y.
    Clin Transplant; 2009 Aug; 23 Suppl 20():39-43. PubMed ID: 19594595
    [Abstract] [Full Text] [Related]

  • 6. Clazakizumab for the treatment of chronic active antibody-mediated rejection (AMR) in kidney transplant recipients: Phase 3 IMAGINE study rationale and design.
    Nickerson PW, Böhmig GA, Chadban S, Kumar D, Mannon RB, van Gelder T, Lee JC, Adler S, Chong E, Djamali A.
    Trials; 2022 Dec 22; 23(1):1042. PubMed ID: 36550562
    [Abstract] [Full Text] [Related]

  • 7. Comparing transplant glomerulopathy in the absence of C4d deposition and donor-specific antibodies to chronic antibody-mediated rejection.
    Torres IB, Salcedo M, Moreso F, Sellarés J, Castellá E, Azancot MA, Perelló M, Cantarell C, Serón D.
    Clin Transplant; 2014 Oct 22; 28(10):1148-54. PubMed ID: 25103874
    [Abstract] [Full Text] [Related]

  • 8. The clinical and genomic significance of donor-specific antibody-positive/C4d-negative and donor-specific antibody-negative/C4d-negative transplant glomerulopathy.
    Hayde N, Bao Y, Pullman J, Ye B, Calder RB, Chung M, Schwartz D, Lubetzky M, Ajaimy M, de Boccardo G, Akalin E.
    Clin J Am Soc Nephrol; 2013 Dec 22; 8(12):2141-8. PubMed ID: 24030736
    [Abstract] [Full Text] [Related]

  • 9. Concurrent acute cellular rejection is an independent risk factor for renal allograft failure in patients with C4d-positive antibody-mediated rejection.
    Matignon M, Muthukumar T, Seshan SV, Suthanthiran M, Hartono C.
    Transplantation; 2012 Sep 27; 94(6):603-11. PubMed ID: 22932115
    [Abstract] [Full Text] [Related]

  • 10. Pathology of C4d-negative antibody-mediated rejection in renal allografts.
    Haas M.
    Curr Opin Organ Transplant; 2013 Jun 27; 18(3):319-26. PubMed ID: 23283250
    [Abstract] [Full Text] [Related]

  • 11. Differences in pathologic features and graft outcomes in antibody-mediated rejection of renal allografts due to persistent/recurrent versus de novo donor-specific antibodies.
    Haas M, Mirocha J, Reinsmoen NL, Vo AA, Choi J, Kahwaji JM, Peng A, Villicana R, Jordan SC.
    Kidney Int; 2017 Mar 27; 91(3):729-737. PubMed ID: 28104301
    [Abstract] [Full Text] [Related]

  • 12. T-bet-positive mononuclear cell infiltration is associated with transplant glomerulopathy and interstitial fibrosis and tubular atrophy in renal allograft recipients.
    Yadav B, Prasad N, Agrawal V, Jain M, Agarwal V, Jaiswal A, Bhadauria D, Sharma RK, Gupta A.
    Exp Clin Transplant; 2015 Apr 27; 13(2):145-51. PubMed ID: 25871366
    [Abstract] [Full Text] [Related]

  • 13. Banff-based histologic chronicity index is associated with graft failure but has poor interobserver reproducibility.
    Lin WC, Wen MC, Hsu YC, Kuo CY, Chen TD.
    Clin Transplant; 2024 Jun 27; 38(6):e15335. PubMed ID: 38804610
    [Abstract] [Full Text] [Related]

  • 14. Molecular diagnosis of antibody-mediated rejection: Evaluating biopsy-based transcript diagnostics in the presence of donor-specific antibodies but without microvascular inflammation, a single-center descriptive analysis.
    Harmacek D, Weidmann L, Castrezana Lopez K, Schmid N, Korach R, Bortel N, von Moos S, Rho E, Helmchen B, Gaspert A, Schachtner T.
    Am J Transplant; 2024 Sep 27; 24(9):1652-1663. PubMed ID: 38548057
    [Abstract] [Full Text] [Related]

  • 15. Reviewing the pathogenesis of antibody-mediated rejection and renal graft pathology after kidney transplantation.
    Morozumi K, Takeda A, Otsuka Y, Horike K, Gotoh N, Narumi S, Watarai Y, Kobayashi T.
    Nephrology (Carlton); 2016 Jul 27; 21 Suppl 1():4-8. PubMed ID: 26971899
    [Abstract] [Full Text] [Related]

  • 16. Antibody-mediated rejection in the Banff classifications of 2007 and 2017: A comparison of renal graft loss prediction capability.
    Solar-Cafaggi D, Marino L, Uribe-Uribe N, Morales-Buenrostro LE.
    Transpl Immunol; 2018 Dec 27; 51():40-44. PubMed ID: 30170180
    [Abstract] [Full Text] [Related]

  • 17. Multiomic profiling of transplant glomerulopathy reveals a novel T-cell dominant subclass.
    Cristoferi I, Varol H, van Baardwijk M, Rahiem L, Lila KA, van den Bosch TPP, Baan CC, Hesselink DA, Kramann R, Minnee RC, Mustafa DAM, Reinders MEJ, Roelen DL, Shahzad-Arshad SP, Smith RN, Stubbs AP, Colvin RB, Rosales IA, Clahsen-van Groningen MC.
    Kidney Int; 2024 Apr 27; 105(4):812-823. PubMed ID: 38128610
    [Abstract] [Full Text] [Related]

  • 18. Highly Sensitized Candidates Remain at Risk for Microvascular Inflammation Even When Donor-specific Antibody Is Avoided: A Matched Cohort Study.
    Agrawal A, Balakrishnan S, Gandhi MJ, Alexander MP, Cornell L, Bentall AJ, Kukla A, Stegall M, Schinstock CA.
    Transplantation; 2024 Sep 01; 108(9):1986-1993. PubMed ID: 38578704
    [Abstract] [Full Text] [Related]

  • 19. Presentation and Outcomes of C4d-Negative Antibody-Mediated Rejection After Kidney Transplantation.
    Orandi BJ, Alachkar N, Kraus ES, Naqvi F, Lonze BE, Lees L, Van Arendonk KJ, Wickliffe C, Bagnasco SM, Zachary AA, Segev DL, Montgomery RA.
    Am J Transplant; 2016 Jan 01; 16(1):213-20. PubMed ID: 26317487
    [Abstract] [Full Text] [Related]

  • 20. Glomerular C4d Immunoperoxidase in Chronic Antibody-Mediated Rejection and Transplant Glomerulopathy.
    Nankivell BJ, P'Ng CH, Shingde M.
    Kidney Int Rep; 2022 Jul 01; 7(7):1594-1607. PubMed ID: 35812271
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 10.